Department of Gastroenterology, Portuguese Oncology Institute of Porto, Porto, Portugal.
CINTESIS (Center for Health Technology and Services Research), Faculty of Medicine, University of Porto, Porto, Portugal.
Scand J Gastroenterol. 2020 Jun;55(6):701-705. doi: 10.1080/00365521.2020.1766553. Epub 2020 May 24.
Surveillance of Lynch syndrome (LS) is recommended to reduce cancer-risk. There is an increased awareness that cancer-risk may vary with mismatch-repair mutation and family history. However, gene-specific and family-specific surveillance are not recommended. Therefore, we aimed to estimate the cumulative incidence of lesions and to assess the cancer-risk by family history and mismatch-repair mutation (MMR). Single-centre retrospective cohort of all individuals ( = 241) in a specialized institution was conducted. Forty-eight percent of individuals inherited MSH2 mutations, 32% MLH1, 15% MSH6 and 5% PMS2. The calculated cumulative incidence for any cancer increased with age. By age 70, the cumulative incidence for low-risk, high-risk adenomas and CRC was estimated at 66.6%, 57.7% and 25.7%, respectively. By age 70, the cumulative incidence of endometrial cancer (EC), gastric cancer and urinary tract cancer was estimated at 17.3%, 3.3% and 12.6%, respectively. MLH1 and MSH2 mutation carriers had lower mean age of CRC diagnosis than MSH6 and PMS2 [MLH1:44(CI95% 38-50); MSH2:43(CI95% 40-47); MSH6:52(CI95% 45-59); PMS2:46(CI95% 35-57)]. The risk of EC was higher when family history was present (RR = 2.39, CI95%[1.3;4.6]). MSH6 mutation carriers had higher risk of EC comparative to other MMR mutation carriers (RR = 1.9, = .09). The risk of urinary tract cancer was higher with MSH2 (RR = 8.4, CI95%[2.7;25.9]) and positive family history (RR = 10.8, CI95%[1.4;82.8]). This cohort demonstrates the effectiveness of LS surveillance and suggests possible tailored surveillance strategies by gene mutation and family history.
林奇综合征(LS)的监测被推荐用于降低癌症风险。人们越来越意识到,癌症风险可能因错配修复突变和家族史而异。然而,不推荐针对特定基因和家族的监测。因此,我们旨在通过家族史和错配修复突变(MMR)来估计病变的累积发生率,并评估癌症风险。对专门机构的所有个体(= 241)进行了单中心回顾性队列研究。48%的个体遗传了 MSH2 突变,32%遗传了 MLH1,15%遗传了 MSH6,5%遗传了 PMS2。任何癌症的累积发生率随年龄增加而增加。到 70 岁时,低危、高危腺瘤和 CRC 的累积发生率估计分别为 66.6%、57.7%和 25.7%。到 70 岁时,子宫内膜癌(EC)、胃癌和泌尿道癌的累积发生率估计分别为 17.3%、3.3%和 12.6%。MLH1 和 MSH2 突变携带者的 CRC 诊断平均年龄低于 MSH6 和 PMS2[MLH1:44(95%CI95% 38-50);MSH2:43(95%CI95% 40-47);MSH6:52(95%CI95% 45-59);PMS2:46(95%CI95% 35-57)]。存在家族史时,EC 的风险更高(RR = 2.39,95%CI[1.3;4.6])。与其他 MMR 突变携带者相比,MSH6 突变携带者 EC 的风险更高(RR = 1.9,=.09)。MSH2 突变(RR = 8.4,95%CI[2.7;25.9])和阳性家族史(RR = 10.8,95%CI[1.4;82.8])会增加泌尿道癌的风险。该队列表明 LS 监测有效,并提示可根据基因突变和家族史制定个性化的监测策略。